Development and Commercialization of near infrared fluorescence probe for Alzheimer's diagnosis

Recent reports suggest that beta-amiroid peptides are a major factor in Alzheimer's disease. Early diagnosis of beta amyloid plaques is very important for the diagnosis and treatment of diseases. In this study, we developed the synthesis technology of near-infrared fluorescent compound that can detect Aβ, one of the main causes of AD, and the real-time detection imaging technology of mouse Aβ. Four novel synthetic compounds were confirmed to have the same structure as the technology transfer compound through 1H-NMR and NRMS analysis. HPLC, UV-Vis spectrophotometer and PL spectrometer, in vivo and ex vivo imaging analysis of four new synthetic compounds showed superior performance compared to competing products and technology transfer compounds. Synthesis and industrial preparation of near-infrared fluorescent compounds for the detection of Aβ-Aβ were established, and its purpose is to commercialize near-infrared fluorescent imaging probes for Aβ small animal imaging. R & D achievements include: 1) Technology transfer of near-infrared fluorescent compound that can detect Aβ, one of the main causes of AD, and Aβ real-time detection imaging technology of mouse using it; 2) Four new synthetic compounds 1H-NMR, NRMS analysis confirmed the same structure as the previous technology, 3) Competitive products and technologies through HPLC, UV-Vis spectrophotometer and PL spectrometer, in vivo and ex vivo imaging analysis of four new synthetic compounds 4) the synthesis and industrial preparation of near-infrared fluorescent compounds for the detection of Aβ were established. The expectation of this study is to commercialize Alzheimer's imaging near-infrared fluorescence probe using domestic technology.